Pharmacokinetics and antimicrobial dosing adjustment in critically ill patient during continous renal replacement theraphy

Clinical Nephrology

Volumn 67, Issue 5, 2007, Pages 267-384

  Kuang, D ^a,b   Verbine, A ^a   Ronco, C ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b FUDAN UNIVERSITY   (China)

Author keywords

Acute renal failure; Antimicrobials; Continuous renal replacement theraphy; Drug elimination; Intensive care unit

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFACLOR; CEFAMANDOLE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; ENOXACIN; GANCICLOVIR; GENTAMICIN; HYPERTENSIVE AGENT; IMIPENEM; INOTROPIC AGENT; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; NAFCILLIN; NETILMICIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTINUOUS RENAL REPLACEMENT THERAPY; COST CONTROL; CRITICALLY ILL PATIENT; DIALYSIS MEMBRANE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FLUID THERAPY; HEMODIAFILTRATION; HEMODIALYSIS; HEMOFILTRATION; HOSPITAL COST; HUMAN; HYPOTENSION; INCIDENCE; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MULTIPLE ORGAN FAILURE; PERITONEAL DIALYSIS; PERITONITIS; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RISK FACTOR; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

EID: 34248352279     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp67267     Document Type: Article

References (47)

1. Angus D, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated cost of care. Crit Care Med. 2001; 29: 1303-1310.
2. Alberti C, Brun-Buisson C, Burchardi H et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intens Care Med. 2002; 28: 108-121.
3. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM. Drug prescribing in renal failure: dosing guidelines for adults (4th ed). Philadelphia: American College of Physicians; 1999.
4. Ashley C, Currie A. The renal drug handbook (2nd ed). Oxford, UK: Radcliffe Medical Press; 2004.
5. Bell M, Liljestam E, Granath F et al. Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. Nephrol Dial Transplant. 2005; 20: 354-360.
6. Bellomo R, Ronco C, Kellum JA, Mehta R, Palevsky P and the ADQI workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Coference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8: R204-212.
7. Bellomo R, Ronco C. Blood purification in the intensive care unit: evolving concepts. World J Surg. 2001; 25: 677-683.
8. Boiler J, Donauer J, Keller F. Pharmacokinetic principle during continuous renal replacement therapy: drugs and dosage. Kidney Int. 1999; 56 (Suppl 72): s24-s28.
9. Brendolan A, D'Intini V, Ricci Z et al. Pulse high-volume hemofiltration. Int J Artif Organs. 2004; 27: 398-403.
10. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand. 2001; 45: 929-934.
11. Calandra T, Cohen J for the International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005; 33: 1538-1548.
12. Corona A, Bertolini G, Ricotta AM et al. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. J Antimicrob Chemother. 2003; 52: 849-852.
13. Harrison D, Welch C, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care. 2006; 10: R42-51.
14. Keller E. Pharmacokinetic during continuous renal replacement therapy. Int J Artif Organs. 1996; 19: 113-117.
15. Keller F, Giehl M, Frankewitsch T, Zellner D. Pharmacokinetics and drug dosage adjustment to renal impairment. Nephrol Dial Transplant. 1995; 10: 1516-1520.
16. Kellum JA, Bellomo R, Ronco C, Mehta R, Clark W, Levin NW. The 3rd International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Int J Artif Organs. 2005; 28: 441-444.
17. Kroh UF. Drug administration in critically ill patients with acute renal failure. New Horiz. 1995; 3: 748-759.
18. Lameire N, van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005; 365: 417-430.
19. Livornese LL Jr, Slavin D, Gilbert B et al. Use of antibacterial agents in renal failure. Infect Dis Clin North Am. 2004; 18: 551-579.
20. MacArthur RD, Miller M, Albertson T et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004; 38: 284-288.
21. Mehta RL, Pascual MT, Soroko S et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004; 66: 1613-1621.
22. Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs. 2003; 27: 808-814.
23. Nicolau DP. Optimizing Outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother. 2003; 9: 292-296.
24. Padkin A, Goldfrad C, Brady AR et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003; 31: 2332-2338.
25. Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the eriticallly ill. Anaesth Intens Care. 2002; 30: 134-144.
26. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin Pharmacokinet. 1993; 24: 162-179.
27. Richards MJ, Edwards JR, Culver DH et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol. 2000; 21: 510-515.
28. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006; 45: 755-773.
29. Ronco C, Bellomo R, Homel P et al. Effects of different doses in continuous venovenous hemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000; 356: 26-30.
30. Ronco C, Bellomo R. Acute renal failure and multiple organ dysfunction in the ICU: From renal replacement therapy (RRT) to multiple organ support therapy (MOST). Int J Artif Organs. 2002; 8: 733-747.
31. Ronco C, Bonello M, Bordoni V et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif. 2004; 22: 164-174.
32. Ronco C, Brendolan A, D'Intini V et al. Coupled plasma filtration adsorption: rationale, technical development and early clinical experience. Blood Purif. 2003; 21: 409-416.
33. Ronco C. Recent evolution of renal replacement therapy in the critically ill patient. Crit Care. 2006; 10: 123-127.
34. Scheetz MH, Scarsi KK, Ghossein C, Hurt KW, Zembower TR, Postelnick MJ. Adjustment of antimicrobial dosages for continuous venovenous hemofiltration based on patient-specific information. Clin Infect Dis. 2006; 42: 436-437.
35. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intens Care Med. 1995; 21: 612-620.
36. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002; 346: 305-310.
37. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. 2004; 351: 159-169.
38. Sweetman S. In: Martindale: The Complete Drug Reference. London: Pharmaceutical Press; 2004.
39. Tillyard A, Keays R, Soni N. The diagnosis of acute renal failure in intensive care: mongrel or pedigree? Anaesthesia 2005; 60: 903-914.
40. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005; 41: 1159-1166.
41. Uchino S, Kellum JA, Bellomo R et al. A multinational, multicenter, prospective, epidemiological study of acute renal failure in critical illness. JAMA. 2005; 294: 813-818.
42. Vidal L, Shavit M, Fraser A et al. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ. 2005; 331: 263-266.
43. Vincent HT, Lomaestro BM. Drug dosing in patients undergoing continuous renal replacement therapy. NY State J Healthsyst Pharmacist. 2001; 20: 10-14.
44. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA. 1995; 274: 639-644.
45. Vincent JL, Jacobs F. Infection in critically ill patients: clinical impact and management. Curr Opin Infect Dis. 2003; 16: 309-313.
46. Vos MC, Vincent HH, Yzerman EP. Clearance of imipenem/cilastatin in acute renal failure patients treated by Continuous hemodiafiltration (CAVHD). Intensive care med. 1992; 18: 282-285.
47. Winter M. Clearance. In: Koda-Kimble M (ed). Basic clinical pharmacokinetics. Vancouver: Applied Therapeutics; 1999. pp. 26-36.